Gossamer Bio (NASDAQ:GOSS) Now Covered by Analysts at Oppenheimer

Oppenheimer began coverage on shares of Gossamer Bio (NASDAQ:GOSS) in a research report report published on Tuesday morning, Marketbeat.com reports. The firm issued an outperform rating and a $9.00 price target on the stock.

Several other brokerages have also weighed in on GOSS. Piper Sandler reissued an overweight rating and issued a $15.00 price objective on shares of Gossamer Bio in a report on Wednesday, March 27th. The Goldman Sachs Group reissued a buy rating and issued a $8.00 price objective on shares of Gossamer Bio in a report on Monday, June 17th. HC Wainwright reissued a buy rating and issued a $10.00 price objective on shares of Gossamer Bio in a report on Monday, May 20th. Finally, Wedbush reaffirmed an outperform rating and set a $4.00 target price on shares of Gossamer Bio in a report on Wednesday, May 8th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and an average price target of $7.88.

Gossamer Bio Trading Up 22.3 %

NASDAQ GOSS opened at $1.01 on Tuesday. The stock has a market capitalization of $228.48 million, a price-to-earnings ratio of -0.95 and a beta of 1.91. Gossamer Bio has a one year low of $0.45 and a one year high of $1.88. The company has a debt-to-equity ratio of 7.37, a current ratio of 7.13 and a quick ratio of 7.13. The business’s fifty day moving average is $0.67 and its 200-day moving average is $0.92.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Tuesday, May 7th. The company reported ($0.19) EPS for the quarter, hitting analysts’ consensus estimates of ($0.19). Equities research analysts predict that Gossamer Bio will post -0.35 EPS for the current year.

Insider Transactions at Gossamer Bio

In other Gossamer Bio news, CEO Faheem Hasnain acquired 372,000 shares of the business’s stock in a transaction dated Friday, June 21st. The stock was bought at an average price of $0.67 per share, with a total value of $249,240.00. Following the completion of the acquisition, the chief executive officer now owns 5,408,073 shares of the company’s stock, valued at $3,623,408.91. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 5.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Sivia Capital Partners LLC bought a new stake in Gossamer Bio in the 1st quarter worth approximately $29,000. Financial Advocates Investment Management lifted its position in Gossamer Bio by 35.0% in the 4th quarter. Financial Advocates Investment Management now owns 98,350 shares of the company’s stock worth $90,000 after buying an additional 25,500 shares during the last quarter. SG Americas Securities LLC bought a new stake in Gossamer Bio in the 1st quarter worth approximately $34,000. Vanguard Group Inc. lifted its position in Gossamer Bio by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 11,763,784 shares of the company’s stock worth $13,881,000 after buying an additional 128,150 shares during the last quarter. Finally, Citigroup Inc. lifted its position in Gossamer Bio by 9,916.9% in the third quarter. Citigroup Inc. now owns 196,732 shares of the company’s stock valued at $164,000 after purchasing an additional 194,768 shares during the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.